XPG (Xeroderma pigmentosum group G complementing factor) is a protein associated with DNA repair and transcription. Point mutations in ERCC5, the gene coding for XPG, cause the cancer-prone disorder xeroderma pigmentosum (XP) while truncation mutations give rise to individuals with the combined clinical features of XP and Cockayne syndrome. Polymorphisms of ERCC5 or alterations in XPG mRNA expression were also associated to an increase risk of different cancers types and to prognosis of cancer patients. However, the expression of XPG protein in different normal or tumor human tissues is not well known. In the present work, we have validated an immunohistochemistry (IHC) assay for detection of expression levels of XPG protein in FFPE human tissue samples. We have also tested this IHC assay in different normal and tumor human tissues. On a microarray containing 28 normal cores, positive staining was observed in 60% of the samples. The highest staining was detected in adrenal gland, breast, colon, heart, kidney, thyroid and tongue. In tumors, positive staining was observed in 9 of 10 breast cancer samples and in all 5 ovarian cancer and 5 sarcomas samples. Subcellular localization was predominantly nuclear. The use of this validated methodology would help to interpret the role of XPG in tumorogenesis and its use as a possible prognostic or predictive factor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544242 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Identification of novel variants of and genes in xeroderma pigmentosum patients in Vietnam.
Per Med
December 2024
Hanoi Medical University, Hanoi city, Vietnam.
Xeroderma pigmentosum (XP) disorder is recognized as a genetic condition inherited by autosomal recessive fashion. XP results from a defective DNA repair mechanism that significantly increases skin cancer risk. Fifteen Vietnamese patients were investigated with typical clinical manifestations of XP.
View Article and Find Full Text PDFDifferent germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients.
PLoS Genet
December 2024
Laboratory of Cancer Biology and Genetics, DNA Repair Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by pathogenic variants in seven nucleotide excision repair genes (XPA to XPG) and POLH involved in translesion synthesis. XP patients have a >1000-fold increased risk for sunlight-induced skin cancers. Many Japanese XP-A patients have severe neurological symptoms due to a founder variant in intron 3 of the XPA gene.
View Article and Find Full Text PDFGenetic variations in NER pathway gene polymorphisms and Wilms tumor risk: A six-center case-control study in East China.
IUBMB Life
December 2024
Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Article Synopsis
- The nucleotide excision repair (NER) system helps protect against DNA damage, and deficiencies in this system can lead to increased mutations and cancer risks.
- A study analyzed 19 NER gene polymorphisms in 416 Wilms tumor cases and 936 controls from East China, finding that certain XPD polymorphisms decreased Wilms tumor risk while some XPG polymorphisms increased it.
- The research suggests that these gene variations affect nearby gene expression and emphasizes the need for further studies with larger sample sizes to validate these associations.
Molecular architecture and functional dynamics of the pre-incision complex in nucleotide excision repair.
Nat Commun
October 2024
Department of Chemistry, Georgia State University, Atlanta, GA, USA.
Article Synopsis
- * Researchers combined techniques like cryo-electron microscopy (cryo-EM), crosslinking mass spectrometry (XL-MS), and AlphaFold2 predictions to create a model of the NER pre-incision complex (PInC), highlighting how proteins interact during DNA repair.
- * The study reveals new insights into how specific proteins (like TFIIH, XPG, and XPF) coordinate their actions, affects DNA binding, and provides explanations for disease-causing mutations related to xeroderma pigmentosum and Cockayne syndrome.
Novel DNA Repair Inhibitors Targeting XPG to Enhance Cisplatin Therapy in Non-Small Cell Lung Cancer: Insights from In Silico and Cell-Based Studies.
Cancers (Basel)
September 2024
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
NSCLC is marked by low survival and resistance to platinum-based chemotherapy. The XPG endonuclease has emerged as a promising biomarker for predicting the prognosis of cisplatin-treated patients and its downregulation having been reported to increase cisplatin efficacy. This study presents an integrated strategy for identifying small molecule inhibitors of XPG to improve cisplatin therapy in NSCLC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!